FSTX News and Press, F-star Therapeutics Inc Com From 11/17/21

The following slide deck was published by F-star Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: F-star Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation

F-star Therapeutics, Inc. (FSTX) Q3 2021 Earnings Conference Call November 10, 2021, 09:00 AM ET Company Participants Lindsey Trickett - VP of IR Eliot Forster - CEO Darlene Deptula-Hicks - CFO Conference Call Participants Hartaj Singh - Oppenheimer & Co. Daina Graybosch - SVB Leerink Jus...

Dr. Michelle Morrow to present on F-star’s Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific Poster Presentation of Preclinical Data Demonstrates Potential for F-star’s FS120 First-in-Class OX40/CD137 Tetravalent Dual T Cell Agonist in...

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. , a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Darlene Deptula–Hicks, Chief Financial Officer of F-star The...

F-star Therapeutics (NASDAQ:FSTX): Q3 GAAP EPS of -$0.52 beats by $0.06. Revenue of $0.75M (-91.8% Y/Y) misses by $1.94M. Press Release For further details see: F-star Therapeutics EPS beats by $0.06, misses on revenue

Company to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispeci...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today ...

LumiraDx (NASDAQ:LMDX) +37% after approval for COVID-19 antigen test in India Troika Media (NASDAQ:TRKA) +32%. Puhui Wealth Investment Management (NASDAQ:PHCF) +16%. Valneva  (NASDAQ:VALN) +16%. Xiaobai Maimai (NASDAQ:HX) +11%. Cyclerion Therapeutics (NASDAQ:CYCN) +11%. F-star ...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer,...